Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Malignant tumor therapeutic vaccine and composition thereof

A technology for therapeutic vaccines and malignant tumors, applied in the field of therapeutic vaccines for malignant tumors and compositions thereof, can solve problems such as cell fragmentation, and achieve the effects of strong immune antigen specificity and low price

Inactive Publication Date: 2014-10-15
熊慧
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many methods for cell disruption, it is difficult to disrupt cells to the nanometer level with uniform particle size

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Malignant tumor therapeutic vaccine and composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1: the preparation method of lung cancer vaccine:

[0035] 1. Preparation of human TGF-β2 antisense plasmid:

[0036] The cDNA of human TGF-β2 (NCBI Reference Sequence: NM_003238.3, fragment 1369bp-2613bp) was cloned in the reverse direction into the multiple cloning site MCS of pIRESpuro3 vector, which was confirmed by sequencing. Because the pIRESpuro3 vector contains the promoter and enhancer of CMV, it can replicate in mammals; it contains the internal ribosome entry site (internal ribosome entry site, IRES) of encephalitis myocarditis virus and expresses the gene resistant to puromycin, which can make Antisense mRNA of human TGF-β2 is expressed alone in cells, and only cells expressing antisense mRNA of human TGF-β2 can grow stably under the selection of puromycin. The structure of the pIRESpuro3 plasmid is attached figure 1 shown.

[0037] 2. Preparation of Cancer Cell Lines from Human Lung Cancer Tumor Tissue

[0038] 2.1 Chopped tissue

[0039]...

Embodiment 2

[0051] Embodiment 2: Preparation of breast cancer tumor therapeutic vaccine

[0052] 1. Preparation of human TGF-β2 antisense plasmid:

[0053] The cDNA of human TGF-β2 (NCBI Reference Sequence: NM_003238.3, fragment 1369bp-2613bp) was cloned in the reverse direction into the multiple cloning site MCS of pIRESpuro3 vector, which was confirmed by sequencing. Because the pIRESpuro3 vector contains the promoter and enhancer of CMV, it can replicate in mammals; it contains the internal ribosome entry site (internal ribosome entry site, IRES) of encephalitis myocarditis virus and expresses the gene resistant to puromycin, which can make Antisense mRNA of human TGF-β2 is expressed alone in cells, and only cells expressing antisense mRNA of human TGF-β2 can grow stably under the selection of puromycin. The structure of the pIRESpuro3 plasmid is attached figure 1 shown.

[0054] 2. Preparation of Cancer Cell Lines from Human Breast Tumor Tissue

[0055] 2.1 Chopped tissue

[00...

Embodiment 3

[0068] Example 3: Preparation of Ovarian Cancer Tumor Therapeutic Vaccine

[0069] 1. Preparation of human TGF-β2 antisense plasmid:

[0070]The cDNA of human TGF-β2 (NCBI Reference Sequence: NM_003238.3, fragment 1369bp-2613bp) was cloned in the reverse direction into the multiple cloning site MCS of pIRESpuro3 vector, which was confirmed by sequencing. Because the pIRESpuro3 vector contains the promoter and enhancer of CMV, it can replicate in mammals; it contains the internal ribosome entry site (internal ribosome entry site, IRES) of encephalitis myocarditis virus and expresses the gene resistant to puromycin, which can make Antisense mRNA of human TGF-β2 is expressed alone in cells, and only cells expressing antisense mRNA of human TGF-β2 can grow stably under the selection of puromycin. The structure of the pIRESpuro3 plasmid is attached figure 1 shown.

[0071] 2. Preparation of Cancer Cell Lines from Human Ovarian Tumor Tissue

[0072] 2.1 Chopped tissue

[0073...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a malignant tumor therapeutic vaccine and a composition thereof. The malignant tumor therapeutic vaccine is a tumor cell line obtained by culture of a human tumor tissue's cancer cells. A TGF-beta2 antisense plasmid is transfected into the tumor cell line, and the tumor cell line is subjected to inactivation, thus obtaining the malignant tumor therapeutic vaccine. The invention also relates to a malignant tumor therapeutic vaccine composition, which includes the malignant tumor therapeutic vaccine and an immunopotentiator. The malignant tumor therapeutic vaccine provided by the invention can be used for treating the tumor cell sourced patients, and has the advantages of strong immune antigen specificity, repeated preparation and use and low price, and also can be prepared into a vaccine preparation for treatment of other patients suffering a same cancer. Animal experiments confirm that the malignant tumor therapeutic vaccine has a good treatment effect.

Description

technical field [0001] The invention relates to a malignant tumor therapeutic vaccine and its composition. Background technique [0002] At present, malignant tumor is still the number one killer threatening human survival, which seriously interferes with the health of patients and affects the quality of life. The treatment methods mainly include surgery, chemotherapy, radiotherapy and biological therapy. Although most of the tumor cells can be removed by surgery, chemotherapy and conventional treatment and the condition of most patients can be relieved, most of the chemotherapy and radiotherapy have serious side effects on patients. Moreover, these treatment methods cannot achieve the effect of completely eradicating cancer cells, and most patients eventually die of tumor recurrence. Therefore, following surgery, chemotherapy, and radiotherapy, biological therapy has become an important means of comprehensive tumor treatment. At present, tumor biological treatment strateg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K39/00A61P35/00
Inventor 熊慧
Owner 熊慧
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com